| Title: |
Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model |
| Authors: |
Nafisa Neault; Aymeric Ravel-Chapuis; Stephen D. Baird; John A. Lunde; Mathieu Poirier; Emiliyan Staykov; Julio Plaza-Diaz; Gerardo Medina; Francisco Abadía-Molina; Bernard J. Jasmin; Alex E. MacKenzie |
| Source: |
International Journal of Molecular Sciences, Vol 24, Iss 4, p 3794 (2023) |
| Publisher Information: |
MDPI AG |
| Publication Year: |
2023 |
| Collection: |
Directory of Open Access Journals: DOAJ Articles |
| Subject Terms: |
myotonic dystrophy type 1; rare diseases; vorinostat; new treatment; Biology (General); QH301-705.5; Chemistry; QD1-999 |
| Description: |
Myotonic dystrophy type 1 (DM1), the most common form of adult muscular dystrophy, is caused by an abnormal expansion of CTG repeats in the 3′ untranslated region of the dystrophia myotonica protein kinase (DMPK) gene. The expanded repeats of the DMPK mRNA form hairpin structures in vitro, which cause misregulation and/or sequestration of proteins including the splicing regulator muscleblind-like 1 (MBNL1). In turn, misregulation and sequestration of such proteins result in the aberrant alternative splicing of diverse mRNAs and underlie, at least in part, DM1 pathogenesis. It has been previously shown that disaggregating RNA foci repletes free MBNL1, rescues DM1 spliceopathy, and alleviates associated symptoms such as myotonia. Using an FDA-approved drug library, we have screened for a reduction of CUG foci in patient muscle cells and identified the HDAC inhibitor, vorinostat, as an inhibitor of foci formation; SERCA1 (sarcoplasmic/endoplasmic reticulum Ca 2+ -ATPase) spliceopathy was also improved by vorinostat treatment. Vorinostat treatment in a mouse model of DM1 (human skeletal actin–long repeat; HSA LR ) improved several spliceopathies, reduced muscle central nucleation, and restored chloride channel levels at the sarcolemma. Our in vitro and in vivo evidence showing amelioration of several DM1 disease markers marks vorinostat as a promising novel DM1 therapy. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| Relation: |
https://www.mdpi.com/1422-0067/24/4/3794; https://doaj.org/toc/1661-6596; https://doaj.org/toc/1422-0067; https://doaj.org/article/02248837f6264698937e8d5f53f3e0d8 |
| DOI: |
10.3390/ijms24043794 |
| Availability: |
https://doi.org/10.3390/ijms24043794; https://doaj.org/article/02248837f6264698937e8d5f53f3e0d8 |
| Accession Number: |
edsbas.AAB03D26 |
| Database: |
BASE |